Histoprognostic factors of pancreatic adenocarcinoma - Zehani, Alia
32,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
  • Broschiertes Buch

Pancreatic ductal adenocarcinoma (PDA) has a poor prognosis. Identification of the factors that condition its aggressiveness would be crucial. The aim of the study was to determine the histoprognostic factors of resectable PCA and to evaluate the interest of the Epithelial-Mesenchymal Transition (EMT) study. This is a descriptive study of 36 cases of PCA. EMT was assessed by tumor budding and immunohistochemical expression of vimentin and CD44. Conventional PCA was the primary histologic type (78%). The 5-year survival was 5.6%. Age 70 years and expression 5% of vimentin influenced survival in…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Pancreatic ductal adenocarcinoma (PDA) has a poor prognosis. Identification of the factors that condition its aggressiveness would be crucial. The aim of the study was to determine the histoprognostic factors of resectable PCA and to evaluate the interest of the Epithelial-Mesenchymal Transition (EMT) study. This is a descriptive study of 36 cases of PCA. EMT was assessed by tumor budding and immunohistochemical expression of vimentin and CD44. Conventional PCA was the primary histologic type (78%). The 5-year survival was 5.6%. Age 70 years and expression 5% of vimentin influenced survival in univariate analysis. Size 4 cm, presence of tumor remnant, and high-grade budding were independent factors for poor prognosis. Tumor budding was the only independent factor influencing disease-free survival. It was associated with vimentin expression. EMT is a progressive phenomenon of PCA responsible for its aggressiveness and resistance to chemotherapy. Recognition of the mechanismsthat regulate this phenomenon offers hope for targeted therapies.
Autorenporträt
Alia ZEHANI, doctor and university hospital assistant in the Department of Pathological Anatomy at La Rabta Hospital in Tunis.